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Abstract 
Context: Anti-müllerian hormone (AMH) is produced by granulosa cells of small, growing follicles in the 
ovary. Serum AMH levels strongly correlate with the number of growing follicles, and therefore AMH has 
received increasing attention as a marker for ovarian reserve. This review summarizes recent findings 
and limitations in the application of serum AMH in ovarian reserve assessment.
Evidence Acquisition: A PubMed search was conducted to find recent literature on the measurements and 
use of serum AMH as a marker for ovarian reserve.
Evidence Synthesis: Serum AMH levels are measured to assess the “functional ovarian reserve,” a term 
that is preferred over “ovarian reserve,” since AMH levels reflect the pool of growing follicles that potentially 
can ovulate. Serum AMH levels are used in individualized follicle-stimulating hormone dosing protocols 
and may predict the risk of poor response or ovarian hyperstimulation syndrome but has limited value 
in predicting ongoing pregnancy. Serum AMH levels are studied to predict natural or disease-related 
age of menopause. Studies show that the age-dependent decline rates of AMH vary among women. 
The generalized implementation of serum AMH measurement has also led to an increase in diagnostic 
assays, including automated assays. However, direct comparison of results remains problematic.
Conclusion: Serum AMH remains the preferred ovarian reserve marker. However, the lack of an 
international standard for AMH limits comparison between AMH assays. Furthermore, little is known 
about endogenous and exogenous factors that influence serum AMH levels, which limits proper 
interpretation of AMH values in a clinical setting.
Key Words: ovarian reserve, AMH, functional ovarian reserve, menopause, fertility prediction, AMH assays
Introduction
Anti-müllerian hormone (AMH) is a member of the trans-
forming growth factor beta family that has derived its name 
from its role during male sex differentiation by inducing the 
regression of the müllerian ducts. To date, AMH is best known 
as a serum marker for ovarian function, with assessment of 
AMH levels at both ends of the spectrum, that is, ovarian 
reserve and polycystic ovarian syndrome. In the ovary, AMH 
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is expressed by granulosa cells of growing follicles from the 
primary up to the small antral stage. After follicle-stimulating 
hormone (FSH)-dependent selection, AMH expression dis-
appears, although some expression remains in cumulus cells 
of preovulatory follicles. Also, in atretic follicles and corpora 
lutea, AMH expression is lost. This window of expression 
is largely preserved among species and in the adult human 
ovary. Increasing expression levels of AMH are detected in 
follicles up to 8 mm, and expression is absent in follicles >8 
mm. This expression pattern is positively matched by AMH 
concentrations in follicular fluid, showing highest levels in 
follicles up to 8 mm and a sharp drop thereafter (Fig. 1A) (1).
Since AMH is expressed by growing follicles prior to 
FSH-dependent selection and has been shown to be detect-
able in circulation, serum AMH has taken momentum as a 
marker for ovarian function, in particular in the assessment 
of the quantitative aspect of the ovarian reserve, which is 
the focus of this review. By definition, the ovarian reserve 
is constituted by the quality and quantity of the primordial 
follicles, which both decline with increasing age (2). The 
number of growing follicles recruited from the primordial 
follicle pool reflect the number of primordial follicles. 
Since there is no serum marker that directly can measure 
the number of primordial follicles, a marker that reflects 
the number of growing follicles is currently the best proxy 
for the quantitative aspect of the ovarian reserve. Initial 
studies, performed nearly 2 decades ago, showed that serum 
AMH levels indeed strongly correlate with the number of 
growing follicles and that both decline with increasing age 
(3). Based on these initial studies, serum AMH was rapidly 
put forward as an indirect marker for the ovarian reserve 
despite limited knowledge of factors that regulate ovarian 
AMH expression and lack of standardized AMH assays.
Since serum AMH is only an indirect marker, this has led 
to confusion or even misinterpretation of the term ovarian 
reserve. To make a clear distinction between the pool of 
resting primordial follicles and the pool of growing follicles, 
the term functional ovarian reserve (FOR) has been sug-
gested (4). FOR constitutes the pool of follicles 2 to 5 mm 
in diameter from which 1 follicle is destined to be selected 
by FSH and to ovulate (4, 5). This pool of growing follicles 
is known as the AMH-producing follicles, and thus serum 
AMH levels directly reflect FOR (Fig. 1B). In the clinical 
application of serum AMH to assess the ovarian reserve, 
it is therefore more accurate to use the term FOR. The im-
portance to distinguish between ovarian reserve and FOR 
in the interpretation of AMH levels is illustrated by mouse 
studies and the scarce human studies in which the number 
of primordial follicles were determined. In mice, AMH levels 
remained constant at younger ages despite declining prim-
ordial follicle numbers. Only at older ages did AMH levels 
reflect the number of primordial follicles, while at all ages, 
serum AMH levels correlated with the number of growing 
follicles (6). Similar findings were observed in human studies 
in which the density of primordial and primary follicles was 
directly determined in ovaries removed because of benign 
gynecologic indications or prior to gonadotoxic therapies. 
In younger women AMH levels did not correlate, while in 
women of late reproductive age, a significant correlation was 
observed with the primordial follicle density (7-10). These 
studies suggest that at all ages serum AMH levels reflect 
FOR, and only at older reproductive ages, AMH levels may 
also reflect the ovarian reserve. Therefore, in this review, we 
will use the term FOR in order to discuss recent insights and 
limitations in the use of serum AMH to predict age of meno-
pause in healthy women and in disease conditions.
Serum AMH Levels in the General Population
Serum AMH levels are negatively correlated with age in 
adult women. However, studies aimed to develop norma-
tive data for AMH also showed that this correlation de-
pends on the age category analyzed. From birth onward, 
Figure 1. Anti-müllerian hormone expression and concentration in re-
lation to folliculogenesis and ovarian reserve. (A) Anti-müllerian hor-
mone (AMH) expression increases from the secondary stage onward 
until the small antral follicle stage. In preovulatory follicles, AMH is only 
expressed in cumulus granulosa cells surrounding the oocyte (dark pink 
layer). (B) With increasing age, the functional ovarian reserve decreases 
as a result of exhaustion of the primordial follicle pool. This leads to a 
decrease in the number of small antral follicles and consequently to a 
decrease in serum AMH levels, reaching undetectable levels at meno-
pause. Figure created with Biorender.
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AMH levels increased to plateau at approximately age 
25 years (11, 12). Up to the age of approximately 16 
years, AMH levels clearly were positively correlated 
with age. This positive correlation may reflect the in-
creased rate of primordial follicle recruitment observed 
from birth up to approximately age 14 years (13). From 
age 25 years onward, AMH levels start to decline to un-
detectable levels at menopause, and only from this age 
onward, a negative correlation between AMH levels and 
age can be observed (11, 12). This pattern across ages 
appears consistent among different ethnicities (14-16). 
However, studies indicate that at any given age, there is 
a considerable variation in serum AMH levels (14, 17, 
18). Thus, similar to what has been observed for an-
tral follicle count (AFC), large interindividual variation 
exists for AMH levels (19, 20). Ethnicity may contribute 
to this variation and should be taken into account when 
interpreting AMH values. Although peak AMH levels 
at age 25 years were higher in Chinese women com-
pared with European women, the age-related decline in 
Chinese women was greater leading to 28% and 80% 
lower AMH levels at age 30 and 45 years, respectively 
(21). In addition, African American women appeared 
to have lower serum AMH levels compared with White 
women but with a slower age-dependent decline (22, 
23).
Serum AMH levels are generally measured during the 
early follicular phase, similar to other hormonal markers 
of ovarian function, such as FSH, estradiol, and inhibin 
B. However, it has been questioned whether the vari-
ations in serum AMH levels could be explained by dif-
ferences during the menstrual cycle. While initial studies 
suggested that AMH levels are relatively stable during 
the menstrual cycle (24), more recent research suggest 
that AMH levels show significant intracycle variation up 
to 20.7% (25-27). Although the small number of indi-
viduals analyzed in these studies is a limitation, a clear 
pattern across the menstrual cycle, as evident for FSH or 
estradiol, was not present. Rather, the variation in AMH 
levels reflects the variation in AFC during the menstrual 
cycle according to a study by Overbeek et al in regularly 
cycling women (28). In this study, it was also shown that 
women with higher basal AMH levels, mostly younger 
women, had relatively higher variation in AMH levels 
across the menstrual cycle (28). Furthermore, studies ob-
served that the intercycle variation in AMH can range 
from 28% to 163%, depending on the AMH assay used 
(27, 29). This intra-individual variation suggests that 
a single AMH measurement may lead to an inaccurate 
assessment of the FOR, which may have clinical conse-
quences when the AMH value is used in an individual-
ized ovarian stimulation protocol.
Measurement of Serum AMH
AMH is produced as a 140-kDa disulfide-linked 
homodimer (proAMH), consisting of covalently bound 
monomers each of 560 amino acids (aa) (30). The 
AMH proprotein requires cleavages at its monobasic 
cleavage site at aa451 to generate an 110kDa N-terminal 
proregion (AMHN) dimer and a 25kDa C-terminal ma-
ture region (AMHC) dimer, which together form a stable 
noncovalently bound complex (AMHN,C) (31-33). In vitro 
studies using fetal rat testes and cell lines suggest that 
proteolytic cleavage of AMH occurs after secretion and 
is required to become biologically active (32). An add-
itional cleavage site at aa229, of which the impact on 
AMH function remains to be determined, generates po-
tentially 3 additional AMH isoforms, namely a shorter 
N-terminal peptide (AMHN,229), a mid-region (AMHM) 
and a mid-mature region (AMHM,C) (Fig. 2A).
The clinical importance of AMH measurement has 
led to the development of several AMH assays. Current 
frequently used manual assays include the modified 
Gen II assay (Beckman Coulter) and the ultra-sensitive 
AMH enzyme-linked immunosorbent assay (ELISA) and 
picoAMH assay (both Ansh Labs), which use different 
antibodies than the Gen II AMH assay (Fig. 2B). The 
picoAMH ELISA has an improved sensitivity in the lower 
range, resulting in a limit of detection of 1.3 pg/mL com-
pared with 0.08 ng/mL for the Gen II assay (Fig. 2B). This 
difference in sensitivity may be of clinical importance when 
assessing serum AMH levels, particularly in cases where a 
low ovarian reserve is suspected. Furthermore, currently 
two automated AMH assays, Access AMH (Beckman 
Coulter) and Elecsys AMH (Roche), are available. These 
automated assays use the same antibody pair as the Gen 
II assay (Fig. 2B). Nevertheless, direct comparison of 
AMH values obtained by these assays is still problematic. 
Differences in values could be explained by the use of dif-
ferent antibody pairs (for the manual assays), which could 
lead to detection of different AMH isoforms. Sample in-
stability or a matrix effect, which affects interlaboratory 
reproducibility, could contribute as well. The development 
of automated assays has increased assay precision, repro-
ducibility, and speed of measurement, and therefore are su-
perior over the manual assays.
Several studies have compared the manual and auto-
mated assays and present regression equations to allow 
comparison of serum AMH levels measured by different 
assays (34-38). However, as shown in Table 1, depending 
on the study and the level of AMH, the degree and the dir-
ection of conversion changes considerably. For instance, 
an AMH level of 1 ng/mL yielded a variation ranging 
from –12.8% to –25.2%, when comparing the Elecsys 
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automated assay with the Gen II ELISA in the various 
studies. However, an AMH level of 5 ng/mL gives a vari-
ation ranging from –24% to +45% (34-36). Similar re-
sults were found when comparing the Gen II ELISA with 
the Access automated assay (36-38). The correlation 
varied from –9% to +34% and –19.4% to +7% for 1 ng/
mL and 5 ng/mL AMH, respectively. Although the im-
pact of this variation on absolute AMH values may not 
seem that large, these changes will impact AMH cutoff 
values and subsequently clinical decision-making in fer-
tility treatment.
These differences between assays depending on AMH 
levels remain puzzling and contribute to conflicting results 
in clinical studies assessing AMH. The lack of an inter-
national AMH standard, even 20 years after the devel-
opment of the first AMH ELISA assay, is one of the main 
problems hampering AMH assay comparison. Absence of 
uniformly calibrated assays limit the development of stand-
ardized AMH cutoff values needed to enhance patient 
safety and to prevent misinterpretation by clinicians un-
aware of this interassay variability.
The differences might be partly explained by a wide 
variation in population characteristics. Some studies have 
included women undergoing in vitro fertilization (IVF) 
treatment, whereas others included women undergoing 
laparoscopic sterilization or samples with an unclear clin-
ical status related to fertility. Moreover, the sample size 
was relatively small (ranging from 23 women to 142 
women), and also the age range was quite variable (23-56 
years). Therefore, more research is needed to allow proper 
comparison of the different assays, using larger, clearly de-
fined cohorts stratified by age.
Figure 2. Potential anti-müllerian hormone (AMH) isoforms and AMH assay characteristics. (A) Illustration of the possible AMH isoforms present in 
the circulation. The black dotted lines represent the cleavage sites at amino acids 229 and 451, respectively. The N-terminal proregion is shown in 
green, and the C-terminal mature region is shown in red. (B) Depicts the characteristics of the different AMH assays. The capture antibody is shown 
in purple, and the detector antibody is shown in orange. The assay type, limit of detection, and the measurement range of the different AMH assays 
are shown in the table below. Figure created with Biorender.
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article/105/11/dgaa513/5890022 by Erasm
us U
niversiteit R
otterdam
 user on 23 Septem
ber 2020
5  The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 11
In addition, in the development of an AMH international 
standard, it is important that the existence and clinical rele-
vance of different AMH isoforms are unraveled. Current 
assays detect proAMH and AMHN,C. However, little is 
known about the presence and concentration of other AMH 
isoforms in the circulation. Although the AMHC fragment is 
the biologically active form of AMH, Pankhurst et al sug-
gest that it is not detectable in circulation (39). This might 
indicate that AMHC is only generated after receptor binding 
of the AMHN,C isoform, as shown in vitro (40). In a recent 
study by Wissing et al (41), it was shown that the amount 
of uncleaved AMH (proAMH) in normoovulatory women 
is only 3% of the total promature isoforms (proAMH and 
AMHN,C). This result was obtained using Ansh Labs ELISAs 
that either use a different antibody pair or sample treatment 
to distinguish the different isoforms (41). This suggests that 
the majority of serum AMH levels represents cleaved AMH. 
However, results should be interpreted with caution as ma-
trix effects could alter the isoform conformation, limiting 
direct comparison of values.
Currently, it is unknown whether processing of AMH dif-
fers with age, by clinical condition, or even among women. 
Thus, it remains to be determined whether measurement of 
different AMH isoforms or their ratio has improved clinical 
relevance over total AMH, as assessed by current assays.
Influencing Factors of Serum AMH
To properly interpret serum AMH levels, knowledge of fac-
tors that influence AMH levels is crucial. The majority of 
women of reproductive age use a type of hormonal contra-
ceptive (HC), yet reported effects of HC use on serum 
AMH levels are conflicting. A systematic review by Amer 
et al (42), reassessing 15 studies, concluded that serum 
AMH levels in normoovulatory women decreased when 
HC was used for at least a year, and this effect was in the 
majority of the studies reversible after discontinuation of 
HC use. However, the extent of decline ranged from 14% 
to 55%, which could be explained by differences in type 
of HC use, duration of use, timing of AMH measurement 
during the menstrual cycle, and AMH assays used. Indeed, 
Landersoe et al (43) showed in a retrospective study that 
serum AMH levels were 30% to 40% lower in women 
using the oral contraceptive or the progesterone-only pill, 
while in women using an intrauterine device, only a de-
crease of 17% was observed. In addition, both studies re-
ported a decline in AFC (42, 43), strongly suggesting that 
the change in serum AMH levels caused by HC use results 
from a change in follicle dynamics rather than a direct 
effect on AMH gene regulation. However, a direct effect of 
an altered gonadotropin and sex steroid milieu on AMH 
expression cannot be ruled out.
Several studies have identified body mass index (BMI) 
to negatively influence AMH levels. In a study by Moslehi 
et al (44) reanalyzing 26 studies, patients were subdivided 
into a fertile group without polycystic ovary syndrome 
(PCOS), an infertile non-PCOS group, and a PCOS group. 
The authors found a negative correlation between BMI 
and AMH in all groups, with a Fisher Z statistic of –0.15 
(95% confidence interval [CI] –0.20 to –0.11) in the total 
population. However, BMI did not correlate with AFC, 
suggesting that BMI might directly affect AMH levels and 
not the FOR. Although the exact mechanism remains to 
be unraveled, leptin is thought to play a role. Merhi et al 
Table 1. Comparison of regression equations between anti-müllerian hormone assays
Paper Regression Equation Gen II ng/mL Elecsys  
ng/mL (%)
Access  
ng/mL (%)
Gassner et al, 2014 Elecsys = 0.81*Gen II – 0.046 1 0.76 (–24%)  
5 4.00 (–20%)  
Hyldgaard et al, 2015 Elecsys = 0.68*Gen II + 0.769 1 1.45 (+45%)  
5 4.17 (–16.6%)  
Nelson et al, 2015 Elecsys = 0.73*Gen II + 0.087 1 0.82 (–18%)  
5 3.74 (–25.2%)  
Van Helden et al, 2015 Elecsys = 0.88*Gen II – 0.039 1 0.84 (–16%)  
5 4.36 (–12.8%)  
Nelson et al, 2015 Access = 0.78*Gen II + 0.128 1  0.91 (–9%)
5  4.03 (–19.4%)
Van Helden et al, 2015 Access = 0.91*Gen II – 0.033 1  0.88 (–12%)
5  4.52 (–9.6%)
Pearson et al, 2016 Access = 1.00*Gen II + 0.341 1  1.34 (+34%)
5  5.35 (+7%)
AMH levels of 1 ng/mL and 5 ng/mL measured by the Gen II ELISA were converted using the regression equations of each study to provide values for the Elecsys 
and the Access automated AMH assays.
Abbreviations: AMH, anti-müllerian hormone; ELISA, enzyme-linked immunosorbent assay.
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(45) demonstrated in cultured human granulosa cells, iso-
lated from both small follicles (SFs; <14 mm) and large 
follicles (LFs; ≥14 mm), that treatment with recombinant 
leptin significantly suppressed AMH and AMH receptor 
II messenger ribonucleic acid (mRNA) levels. Treatment 
with a JAK2/STAT3 inhibitor prevented the leptin-induced 
downregulation of AMH mRNA expression, suggesting a 
direct involvement of the leptin signaling pathway. In con-
trast, a more recent study demonstrated that inhibition of 
leptin signaling through transfection of cultured human 
granulosa cells with leptin small interfering RNA (siLeptin) 
significantly reduced AMH secretion (46). It is plausible 
that leptin has different effects on AMH expression and 
secretion. Nevertheless, the precise mechanism remains to 
be elucidated.
Vitamin D (VitD) has increasingly been recognized to 
influence AMH levels. VitD levels exhibit seasonal vari-
ation with higher levels in summer compared with winter. 
Dennis et al (47) demonstrated that AMH levels in women 
of reproductive age also exhibit this seasonal variation, 
with levels being 18% lower in winter than in summer. In 
a subsequent study, healthy normoovulatory women were 
randomized to receive a single oral dose of 1,25-dihydroxy 
vitamin D (VD3), the active metabolite of VitD, or pla-
cebo (48). Within 24 hours after VD3 treatment, serum 
AMH levels sharply rose to 15.8 ± 1.1 nmol/L compared 
with 1.2 ± 0.7 nmol/L in control participants. However, 
the question remains whether VD3 increases serum AMH 
concentration directly via regulation of AMH expres-
sion or indirectly via a change in granulosa cell number. 
To address this question, Xu et al (49) investigated the 
effects of VD3 treatment on follicular development and 
AMH concentrations in macaques by culturing growing 
follicles in the presence of VD3. Analysis showed that VD3 
increased preantral follicle survival, and AMH levels were 
significantly higher compared with controls (49). During 
the first 2 weeks of culture, VD3 treatment did not alter the 
follicular development or the hormonal milieu. However, 
during weeks 3 through 5, VD3 exposure increased antral 
follicle survival and AMH concentrations, while mRNA 
levels of AMH and AMH receptor II remained unchanged 
(50). These findings suggest that VD3 prevents granulosa 
cell apoptosis rather than directly regulating AMH expres-
sion, as also suggested by Merhi et al (51). In their study, 
VitD treatment did not affect AMH mRNA expression but 
rather inhibited AMH-induced signaling. This could lead 
to accelerated follicle maturation, which would explain 
the observed negative correlation between follicular fluid 
VitD levels and AMH mRNA expression (51). However, a 
direct effect on AMH expression cannot be ruled out since 
a VDR response element has been mapped to the AMH 
promoter (52).
These studies suggest that when counseling women on 
their FOR based on AMH levels, insight into factors that 
influence AMH expression but also follicle dynamics is im-
portant. It remains to be determined whether changes in 
AMH expression also lead to changes in number of prim-
ordial follicles, that is, the ovarian reserve, and whether 
such changes are in the same direction. This emphasizes 
the use of FOR over ovarian reserve in relation to AMH 
assessment.
Use of Serum AMH Levels in the Prediction of 
Age of Menopause
In the Western world, the age at which a woman decides 
to have her first child has increased, and thereby also 
the risk of age-related involuntary infertility (53). Given 
the strong correlation between the age-related decline in 
primordial follicle number, number of growing follicles, 
and serum AMH levels, several studies have investigated 
whether serum AMH could aid in the prediction of age 
of menopause. A meta-analysis by Depmann et al (54), in 
which AMH levels from 6 studies were reanalyzed, con-
cluded that serum AMH can predict time to menopause. 
However, compared with a woman’s age, the added value 
of serum AMH was limited as the C statistic only in-
creased from 84% to 86%. Furthermore, serum AMH 
appeared to have limited precision on an individual level. 
Conflicting results have been reported in the prediction of 
onset of menopause in women of late reproductive age. 
In a recent population-based study, of which the majority 
of women were overweight or obese, it was shown that 
women aged 45 to 49 years with undetectable AMH levels 
had a 60% probability to become menopausal within 5 
years (55). Furthermore, AMH did improve the prediction 
of menopausal onset compared with age alone (C statistic 
91% vs 83%) (55). A recent multiethnic study, which in-
cluded 1537 pre- or early perimenopausal women at base-
line and with follow-up until 12 months of amenorrhea 
was reached (SWAN study), analyzed the prediction of the 
final menstrual period (FMP) by AMH levels. Although 
AMH was serially assessed in a small subset of this cohort, 
multiple samples of individual women were independently 
used in the statistical models to predict FMP. Combined 
with age and BMI, AMH had a better predictive value 
for FMP than FSH. In women younger than age 48 years, 
an AMH value <10 pg/mL had a 51% positive predictive 
value to predict reaching FMP within 12 months, which in-
creased to 78% when reaching FMP within 36 months. In 
women aged ≥51 years, these values were 79% and 97%, 
respectively. Importantly, extending prediction of FMP 
within 12 months to within 36 months decreased the sen-
sitivity of AMH significantly. In contrast, in women aged 
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article/105/11/dgaa513/5890022 by Erasm
us U
niversiteit R
otterdam
 user on 23 Septem
ber 2020
7  The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 11
<45 years, an AMH <10 pg/mL had a low sensitivity and 
low positive predictive value in prediction FMP (56). Thus, 
combined these 2 latter studies suggest that in women of 
late reproductive age, assessment of AMH may aid in the 
prediction of age of menopause. However, it can be argued 
that prediction of age of menopause at a younger age is 
clinically more relevant for an individual woman, as is pre-
diction of early menopause, that is, menopause before the 
age of 45 years.
In the above-discussed meta-analysis by Depmann et 
al (54), compared with age alone, AMH increased the 
C statistic from 52% to 80% in the prediction of early 
menopause. In a recent prospective study with a nested 
case-control design containing 327 cases, the use of serum 
AMH to predict early menopause was confirmed. A de-
crease of 0.10 ng/mL in AMH increased the risk of early 
menopause by 14% (95% CI, 1.10-1.18). Compared with 
an AMH level of 2.0 ng/mL, the odds ratio (OR) for early 
menopause was 23 for women with an AMH level of 0.5 
ng/mL (57).
Most prediction models are based on a single AMH 
measurement and assume a comparable decline pattern in 
each woman. Recent studies analyzing longitudinal AMH 
measurements suggest that AMH may not follow a uni-
form decline trajectory. Analysis of the population-based 
Doetinchem cohort study with data available from 5 visits 
over a 20-year follow-up period, showed an age-dependent 
decline in AMH levels, which varied significantly for in-
dividual women. Furthermore, it was shown that the de-
cline rate changed with age, accelerating after the age of 
40 years (58). Hence, it has been suggested that using in-
dividual AMH decline patterns may improve the predic-
tion of age of menopause. However, reanalyzing data of 
2432 women from the Doetichem cohort study showed 
that an AMH decline rate alone, or in combination with 
age-specific AMH, had little additional value (59). In con-
trast, an Iranian study analyzing longitudinal data of 959 
women during a follow-up of 14 years, of whom 55% 
reached menopause, did show that serial measurements of 
AMH improved the prediction of age of menopause, since 
addition of AMH decline rate to the model increased the C 
statistic to 78% compared with 70% for AMH alone (60). 
In a smaller subset of this cohort (n = 266) with shorter 
follow-up (average of 6.5 years with 3-year intervals), the 
authors previously confirmed that the decline rate of AMH 
was specific for each woman (61). Importantly, the authors 
also showed that the decline rate was dependent on age, 
which raises the question to at which age interval and how 
frequently AMH should be measured to accurately predict 
age of menopause.
Although the study of Ramezani Tehrani et al (60) did 
not specifically analyze prediction of early menopause, the 
authors did show that the predictive added value of an 
AMH decline rate was consistent when analyzing women 
younger or older than age 40 years. Based on their model, 
women with an AMH value of 0.1 ng/mL at the age 30 
years have a predicted median age of menopause of 43.18 
(37.56-46.33) years with a fifth percentile AMH decline 
rate, while with a 95th percentile decline rate, this is pre-
dicted at 33.63 (29.25-36.08) years (60). Similar to age of 
menopause, in the statistical models of de Kat et al (59), 
an AMH decline rate did not improve prediction of early 
menopause. In fact, in women younger than age 30 years, 
AMH levels may actually underestimate the risk of early 
menopause (59). While this outcome seems to contra-
dict the studies discussed above, when validated, it may 
have clinical consequences since, particularly, women of 
this age category may deliberate whether or not to delay 
childbearing.
Based on current studies, the predictive value of serum 
AMH for age of menopause remains controversial. The 
majority of these studies have analyzed different age 
ranges, duration of follow-up, and AMH assays, making 
direct comparison of studies difficult. It also remains un-
clear whether current results obtained in regularly cycling 
women can be translated to infertile women in whom the 
ovarian reserve may be compromised. The potential im-
pact of ethnicity on AMH decline rates also has not been 
analyzed in much detail. Thus, validation studies that 
incorporate additional variables are required to deter-
mine specific AMH thresholds in the prediction of age at 
menopause.
Use of AMH Levels in the Prediction of 
Response to Controlled Ovarian Stimulation
Previous studies have also shown that AMH levels 
may aid in the prediction of ovarian response to con-
trolled ovarian hyperstimulation (COH) protocols. Low 
AMH levels are correlated with a low response, defined 
as retrieval of less than 5 oocytes or cycle cancellation. 
Currently, 2 different ovarian stimulation approaches are 
widely used: a gonadotropin-releasing hormone agonist 
or a gonadotropin-releasing hormone antagonist in 
combination with recombinant or urinary FSH (62). To 
improve the response to COH, algorithms are used to cal-
culate the individualized dosage of FSH. Recently, serum 
AMH measurement has been added to the list of factors, 
which include age, BMI, duration of subfertility, basal 
FSH, and AFC. The algorithms that include measurement 
of FSH, AFC, and AMH are called the ovarian reserve 
tests (ORTs).
Accurate and reliable calculation of the individual 
dosage is important since both under- and overstimulation 
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could lead to cycle cancellation. In addition, an exces-
sive response could result in the development of ovarian 
hyperstimulation syndrome, a potentially life-threatening 
condition. It is, however, unclear whether the use of these 
clinical characteristics significantly improves the prediction 
of ovarian response and clinical outcomes. Broer et al per-
formed 2 meta-analyses to investigate the added value of 
ORTs to the patients’ characteristics of age, BMI, and dur-
ation of subfertility (63, 64). Of these 6 patient characteris-
tics measured, AMH and AFC had the highest accuracy in 
predicting excessive ovarian response, defined as the yield 
of more than 15 oocytes, and in predicting poor ovarian 
response. The receiver-operation characteristic regression 
analysis for predicting an excessive response showed an 
area under the curve (AUC) of 0.81 (95% CI, 0.76-0.87) 
for AMH and 0.79 (95% CI, 0.74-0.84) for AFC, respect-
ively. Combining these 2 tests slightly improved the model 
(AUC 0.85). In predicting a poor ovarian response, com-
parable results were found with an AUC of 0.78 (95% CI, 
0.72-0.84) and 0.76 (95% CI, 0.70-0.82), respectively (64). 
Based on these studies, AMH and AFC are the best param-
eters to predict poor and excessive ovarian responses to 
COH.
The question remains whether individualizing treatment 
based on these parameters also improves clinical outcomes. 
Based on the studies from Broer et al, both AMH and AFC 
showed a very low predictive value for pregnancy rate after 
IVF, with an AUC of only 0.50 and 0.55, respectively (63, 
64). A more recent meta-analysis further investigated this 
finding by reassessing 20 randomized controlled trials (65). 
In agreement with the studies from Broer et al (63, 64), the 
authors concluded that changing the dosage of stimulating 
medication based on individual ORTs, including AMH, 
does not significantly increase the chances on pregnancy 
and live birth.
Friss Petersen et al (66) investigated the effect of AMH 
alone in an individualized algorithm to dose FSH on the 
intended oocyte retrieval (5-14 oocytes) and clinical out-
comes of patients undergoing IVF. Comparison of an AMH-
based dosage of FSH with a standard dosage showed that 
the percentages of unintended responses (<5 oocytes or >15 
oocytes) were comparable as were the clinical outcomes in 
terms of pregnancy rates and live birth. Hence, although 
AMH is a good predictor for ovarian response to COH, it 
does not improve the pregnancy rate and rate of live birth. 
However, an important note is that in women predicted to 
have an excessive response, individualized treatment based 
on ORTs did result in a slight decrease in the chance of 
developing ovarian hyperstimulation syndrome with an 
OR of 0.58 (95% CI, 0.34-1.00) based on 4 studies (65).
Drawing conclusions based on these findings remains 
complicated as the majority of these studies have used 
different cutoff values for ORTs and used different AMH 
assays. Therefore, the clinical application of AMH levels in 
ORT-based dose adaptation still needs to be demonstrated.
Assessment of the FOR in Autoimmune 
Diseases
Women with autoimmune diseases are at risk for early 
menopause and therefore at increased risk for infertility 
and menopause-associated diseases such as osteoporosis 
and cardiovascular diseases. Hence, several studies have 
analyzed serum AMH levels to evaluate FOR in women 
with autoimmune diseases.
A recent meta-analysis of 19 studies analyzing patients 
with systemic lupus erythematosus concluded that serum 
AMH levels were significantly lower in patients with sys-
temic lupus erythematosus compared with healthy control 
participants (pooled standardized mean differences −0.79; 
95% CI, −1.41 to −0.18). In addition, AMH levels were 
further lowered by the immunosuppressant cyclophospha-
mide (pooled standardized mean differences of −0.58; 95% 
CI, −0.87 to −0.30) (67).
Women with recent-onset rheumatoid arthritis (RA) 
had comparable AMH levels with healthy control parti-
cipants, and methotrexate use did not affect AMH levels 
(68). However, in a subsequent study, lower preconception 
AMH levels were observed in women with RA attempting 
to become pregnant. The authors suggested that disease 
duration might explain this difference. In agreement, other 
studies also reported 1.3-fold lower AMH levels in women 
with RA having a disease duration of >6 years (69, 70). 
In patients with juvenile idiopathic arthritis, nearly 2-fold 
lower AMH levels were measured (71).
In women with autoimmune thyroid disease (ATD), 
conflicting results have been reported. Adolescent girls 
newly diagnosed with ATD had either normal or higher 
AMH levels compared with age- and BMI-matched con-
trol participants (72-74). In adult women, the majority of 
studies reported modest but significantly lower AMH levels 
in women with thyroid dysfunction or confirmed ATD, 
although 1 study observed increased AMH levels (75). A 
direct relationship between altered thyroid hormone levels 
and AMH levels in ATD with or without supplementa-
tion with levothyroxine remains, however, uncertain due 
to conflicting results (76-81). If ATD affects FOR, the de-
gree seems modest at best. However, an impact on COH 
outcome cannot be ruled out yet. Although the presence 
of ATD did not further worsen the response to COH in 
women with low AMH levels, it did impair COH response 
in women with normal AMH levels (82).
Women with type 1 diabetes (T1D) are suggested to 
have an earlier age at menopause (83), although this has 
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been questioned more recently. In women with T1D older 
than age 33 years, 2-fold lower AMH levels were observed, 
and also the percentage of having AMH levels in the meno-
pausal range was nearly 5-fold higher compared with con-
trol participants (84). In contrast, although lower AMH 
concentrations also were observed in a large community-
based population cohort of women with T1D, this was 
only in women younger than age 35 years (85). Finally, 
in a cross-sectional, patient-control study, no differences 
in AMH levels, percentage of menopausal range of AMH 
levels, nor age of menopause were observed (86, 87). These 
inconsistent results could in part be explained by the fact 
that T1D also has a high prevalence of PCOS, which is as-
sociated with elevated AMH levels. The presence of women 
with combined PCOS and T1D therefore potentially may 
have masked effects on AMH levels.
Overall, these recent studies suggest that the relation-
ship between autoimmune diseases and diminished FOR, 
as assessed by AMH, remains inconsistent. Additional well-
controlled studies are needed to analyze the impact of dis-
ease onset, duration, and therapy on AMH levels.
Assessment of the FOR After Cancer 
Treatment
Chemotherapy is known to have adverse effects on ovarian 
function and increases the risk of primary ovarian insuffi-
ciency (POI) posttreatment. In recent years, a number of 
studies have analyzed pre- and posttreatment AMH levels 
in patients with cancer, particularly in breast cancer, being 
the most common cancer in women worldwide. Studies 
agree that upon chemotherapy, AMH levels rapidly de-
cline to (nearly) undetectable levels (88, 89). This rapid 
decline can be explained by the immediate elimination of 
AMH-producing growing follicles. Subsequent recovery 
of ovarian function varies among women. To improve 
counseling of patients with cancer for their future fertility, 
pre- and posttreatment AMH levels have been studied 
to identify women at risk for failure of ovarian recovery. 
Patients with breast cancer who developed POI had lower 
pretreatment AMH levels than those who resumed menses 
(89-91). Indeed, pretreatment AMH levels were predictive 
for chemotherapy-induced POI in patients who were pre-
menopausal with breast cancer. In the study by Anderson 
et al (89), a cutoff pretreatment AMH level of <7.3 pmol/L 
(1.022 ng/mL) yielded an AUC of 0.77 with a sensitivity of 
95% and specificity of 49%, while in the study of Xue et 
al, an AMH cutoff value of 0.965 ng/mL yielded a slightly 
higher AUC of 0.84 with a sensitivity of 74% and specifi-
city of 82% (90, 91). Likewise, pretreatment AMH levels 
may predict ovarian recovery, expressed as an AMH level 
≥1 ng/mL at 12 months postchemotherapy (adjusted OR 
1.659; CI 95%, 1.261-2.182), although the detected value 
was modest after 2 years follow-up (adjusted OR 1.275; CI 
95%, 1.141-1.426) (92). However, individual differences in 
ovarian recovery may limit the predictive value of AMH. 
Decantere et al showed that young patients with breast 
cancer who resumed menses by 6 months posttreatment 
showed an earlier and faster increase in AMH levels than 
those with a slow recovery, despite having similar pretreat-
ment AMH levels and receiving the same chemotherapy 
protocol (93). Interestingly, in the slow recovery group, 
posttreatment AMH levels were lower compared with the 
fast recovery group (93). Indeed, lower posttreatment AMH 
levels also increased the risk of chemotherapy-induced POI 
(89, 94). Although the predictive value of AMH appears in-
dependent of age, studies agree that women younger than 
age 40 years have higher posttreatment AMH levels (89, 
94). Cancer survivors seems to have a similar AMH decline 
rate as control women despite having lower posttreatment 
AMH levels (95). This suggests that in cancer survivors the 
exhaustion of FOR is not accelerated. However, predicting 
their reproductive life span remains challenging and will re-
quire additional longitudinal studies controlled for cancer 
type, age of cancer diagnosis, and treatment regimen. A re-
cent study by Su et al (96), analyzing survivors of breast 
cancer, thyroid cancer, and lymphoma is one of the first 
studies starting to address these limitations. AMH trajec-
tories indeed differed based on the gonadotoxic effect of 
the treatment. While treatment at younger age resulted in 
higher AMH trajectories, this protective effect was nullified 
upon treatment with high gonadotoxic agents (96).
In women treated for differentiated thyroid can-
cers, radioactive iodine (RAI) treatment has been sug-
gested to induce early menopause. Although the impact 
of postsurgical RAI treatment on AMH levels seems less 
severe than chemotherapy, AMH levels did declined by 
at least 50% and only showed a partial recovery (97-
99). Furthermore, the impact of RAI treatment on AMH 
levels was more pronounced in patients aged >35 years 
(97, 99). Thus, similar to patients with breast cancer, the 
ovarian reserve may be relatively protected when thyroid 
cancer is diagnosed at a younger age. However, given the 
strong decrease in AMH levels in younger women, also 
for thyroid cancer, additional prospective studies with 
sufficient follow-up are required.
Conclusion
The improved sensitivity and automation of AMH assays has 
strengthened the role of serum AMH levels as a marker for 
the FOR. Assessment of serum AMH levels in the prediction 
of ovarian response to COH and age of menopause, being ei-
ther natural or iatrogenic, may be useful. However, limitations 
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have also surfaced. For proper interpretation of AMH levels, 
more knowledge is needed on endogenous and exogenous 
factors that regulate AMH expression. Studies further sug-
gest that heterogeneity exists in AMH trajectories, which may 
hamper application in personalized patient counseling. Over 
the last years, the number of assays for AMH measurement 
has increased. However, differences exist between assays. An 
international standard for AMH is therefore urgently needed 
to establish assay-independent cutoff values.
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